ZBIO News & Events

Zenas BioPharma announced that results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis were presented in a late-breaking oral presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2026, which took place from February 5-7, 2026 in San Diego, California. Obexelimab met the primary endpoint, demonstrating a highly statistically significant 95% relative reduction in the cumulative number of new gadolinium-enhancing T1 hyperintense lesions over week 8 and week 12 compared with placebo. Near-complete suppression of new GdE T1 hyperintense lesions, markers of active inflammation, was observed with obexelimab by 8 weeks of treatment and was sustained through week 12. The adjusted mean number of new GdE T1 hyperintense lesions per scan was 0.01 in the obexelimab group compared to 0.23 with placebo. Over weeks 8 and 12, only two new GdE T1 lesions were observed in obexelimab-treated patients compared to 19 in placebo-treated patients, with 97.2% of obexelimab treated patients free from T1 lesions over this period. Consistent with the inhibitory mechanism of obexelimab, mean B cell values remained within the normal range for obexelimab-treated patients. The safety profile of obexelimab was consistent with that observed in prior completed trials, including cases of infections and hypersensitivity, most commonly mild injection site reactions. Separately announced 24-week data further confirm the robust and durable activity of obexelimab. The highly statistically significant reductions in total GdE T1 lesions observed with obexelimab over weeks 8 and 12 were maintained through week 24; unadjusted means were 0.87 at baseline, 0.08 at week 12 and 0.04 at week 24 for obexelimab indicating a 95% reduction. Obexelimab meaningfully reduced serum Neurofilament Light by 40% through week 24; 15.28 pg/mL at baseline declining to 12.7 pg/mL at week 12 and 9.2 pg/mL at week 24. New and/or enlarging T2 lesions were also lower in the obexelimab arm and the Expanded Disability Status Scale scores were stable, indicating a lack of progression in physical disability. No new safety signals were observed at week 24.

The major averages finished the first day of the first full trading week of the new year broadly higher as energy and defense stocks were among the leaders after a dramatic weekend in geopolitics. The United States captured Venezuelan President Nicolas Maduro, and traders appear to be pricing in potential long-term implications for U.S. oil access and defense spending, even as oil prices themselves have been mixed.The geopolitical shock has added a dose of uncertainty, but did not trigger any type of broad market panic. Instead, some investors are seeing it as a catalyst for sector rotation. Precious metals continue drawing interest, with gold climbing nearly 3% towards a record high, reflecting traditional haven demand as geopolitical risk re-enters the picture.At the same time, traders may have been looking past this weekend's developments toward a busy week of economic data, including employment and manufacturing reports that could reshape the outlook for Federal Reserve policy in 2026.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Shares of oil majors Chevron, Halliburton, Exxon Mobil, and Baker Hugheswere rising af the U.S. is expected to bein Venezuela's oilVersanthasfrom Comcastand has commenced trading on NasdaqNovo Nordisk'sWegovy pill isQXOannounced a $1.2B convertibleled by Apollo GlobalToyotareported Q4 North America2. WALL STREET CALLS:IBMto Buy from Hold at JefferiesFortiveto Underperform from Outperform at MizuhoCostcoto Outperform at MizuhoAdobeto Hold at JefferiesDuolingoto Buy at BofA on underappreciated entertainment value3. AROUND THE WEB:Omnicomis working with Googleto create a new agent, Digiday reportsSamsungplans to double the number of mobile devices it produces with the "Galaxy AI" feature, which is powered by Google'sGemini, Reuters saysLondon is set to become the first city where both U.S. and Chinese robotaxis operate, as Waymoand Baiduprepare to launch their robotaxis in the city in 2026, FT reportsCiscois in advanced talks to acquire cybersecurity company Axonius for $2B, CTech reportsPalo Alto Networksis in talks to acquire Israeli cybersecurity startup Koi for $400M, CTech reports4. MOVERS:GH Researchincreases after U.S. FDAon its Investigational New Drug Application for GH001Altimmunegains after receiving the U.S. FDAfor pemvidutideKosmoshigher afterZenas BioPharmalower after announcing its Phase 3met its primary endpointOmnicomfalls after BofAthe stock to Underperform5. EARNINGS/GUIDANCEAmpliTech Groupfor FY25 and FY26Healthy Choice WellnessCrineticsreported Q4 PALSONIFY U.S.Commercial Metalson January 8, 2026PriceSmarton January 7, 2026INDEXES:The Dow rose 594.79, or 1.23%, to 48,977.18, the Nasdaq gained 160.19, or 0.69%, to 23,395.82, and the S&P 500 advanced 43.58, or 0.64%, to 6,902.05.